Consensus Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 00:00:00 29/10/2026 +04			5-day change	1st Jan Change
529.69 ^USD	+1.66%		+0.99%	+16.84%

10-28	ConvaTec to Spend GBP500 Million on New Global R&D Hub in Manchester, England, Over Next Decade	MT
10-24	Vertex Pharmaceuticals Incorporated Presents at American Society of Nephrology Kidney Week 2026, Oct-23-2026 06:15 PM

Evolution of the Average Target: Vertex Pharmaceuticals Incorporated

Evolution of the Target Price: Vertex Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated

d69e25e2d69903aa499ef01fae9.mvzRDT5t5Duv0FnTE91AxaTFAGdOVPwsrN1zMVuA8f4.9I6GbwkPrkPqkRqgK44ztpezSyN3Zb9O7pI2fBLCo6HgurdnfVqla8bpFA~c52d45e51dd6cb67d877a109a8acdf77

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

10-22	5 Healthcare Stocks to Watch as Investors Look Beyond Big Tech
10-15	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
10-08	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
08-04	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
08-04	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
08-04	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
07-13	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
07-09	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
07-08	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERTEX PHARMACEUTICALS INCORPORATED					+7.89%
	ELI LILLY AND COMPANY					+3.53%
	JOHNSON & JOHNSON					+3.09%
	ABBVIE INC.					-0.98%
	ROCHE HOLDING AG					-2.95%
	MERCK & CO., INC.					+13.36%
	NOVARTIS AG					-1.36%
	ASTRAZENECA PLC					+23.73%
	AMGEN INC.					-12.06%
	GILEAD SCIENCES, INC.					+0.62%
	Average					+3.49%
	Weighted average by Cap.					+3.16%